✦ LIBER ✦

9430 Efficacy and toxicity of sorafenib in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy

✍ Scribed by Bertuzzi, A.; Stroppa, E.; Secondino, S.; Zucali, P.; Quagliuolo, V.; Pedrazzoli, P.; Comandone, A.; Basso, U.; Parra, H. Soto; Santoro, A.

Book ID: 123270720
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 42 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)72018-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of intravenous TZT-1027 i

Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy

✍ Shreyaskumar Patel; Mary Louise Keohan; M. Wasif Saif; Daniel Rushing; Luis Baez 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB 👁 2 views

Results of randomised studies of the EOR

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

✍ A.T van Oosterom; H.T Mouridsen; O.S Nielsen; P Dombernowsky; K Krzemieniecki; I 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 192 KB

Efficacy and safety of pharmacological i

Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review

✍ Sharma, Sheetal; Takyar, Shweta; Manson, Stephanie C; Powell, Sarah; Penel, Nico 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 417 KB

Prediction of chemotherapy outcome in pa

Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis

✍ Antonia Dimitrakopoulou-Strauss; Ludwig G. Strauss; Gerlinde Egerer; Julie Vasam 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 301 KB

Brostallicin versus doxorubicin as first

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study

✍ Gelderblom, H.; Blay, J.Y.; Seddon, B.M.; Leahy, M.; Ray-Coquard, I.; Sleijfer, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 758 KB